<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383094</url>
  </required_header>
  <id_info>
    <org_study_id>170862</org_study_id>
    <nct_id>NCT03383094</nct_id>
  </id_info>
  <brief_title>Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer</brief_title>
  <official_title>Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (KeytrudaÂ®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loren Mell, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare any good or bad effects of using pembrolizumab (an&#xD;
      experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and&#xD;
      radiation therapy (RT) in the treatment of patients with head and neck squamous cell&#xD;
      carcinoma (HNSCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi-institutional, open-label, randomized phase II trial that&#xD;
      will evaluate the efficacy of concurrent and adjuvant pembrolizumab with radiation therapy&#xD;
      (RT) versus RT plus cisplatin in intermediate/high-riskp16-positive locoregionally advanced&#xD;
      head and neck squamous cell carcinoma (HNSCC). The primary endpoint is progression-free&#xD;
      survival (PFS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from randomization to progression/relapse or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Toxicities due to therapy occurring within 3 months of therapy completion based on CTCAE criteria using questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Toxicity due to therapy occurring greater than 3 months after completion of therapy based on CTCAE criteria using questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of failure</measure>
    <time_frame>3 years</time_frame>
    <description>Local and regional and distant recurrence of cancer and causes of death from competing events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PD-L1 expression correlations</measure>
    <time_frame>3 years</time_frame>
    <description>compare the outcomes with RT/pembrolizumab in patients with tumors as a function of PD-L1 expression.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Cancer</condition>
  <condition>Cancer of Head and Neck</condition>
  <condition>Cancer, Advanced</condition>
  <condition>Cancer, Metastatic</condition>
  <condition>Tumor</condition>
  <condition>Tumor Recurrence</condition>
  <condition>Tumor Neck</condition>
  <condition>Tumor Metastasis</condition>
  <condition>Oral Cancer</condition>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Oropharynx Cancer, Stage III</condition>
  <condition>Oropharynx Cancer, Recurrent</condition>
  <condition>Oropharynx Cancer, Metastatic</condition>
  <arm_group>
    <arm_group_label>Control-radiotherapy/cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent cisplatin 100 mg/m2 every 3 weeks for 3 cycles (7 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental-Radiotherapy/pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent and adjuvant pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles</description>
    <arm_group_label>Experimental-Radiotherapy/pembrolizumab</arm_group_label>
    <other_name>Immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>70 Gy in 33-35 fractions</description>
    <arm_group_label>Control-radiotherapy/cisplatin</arm_group_label>
    <arm_group_label>Experimental-Radiotherapy/pembrolizumab</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>100 mg/m2 Weeks 1, 4, and 7.</description>
    <arm_group_label>Control-radiotherapy/cisplatin</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  p16-positive squamous cell carcinoma of the pharynx, larynx or oral cavity&#xD;
&#xD;
          -  High-Intermediate Risk Disease, defined as:&#xD;
&#xD;
               -  T1-T3 N2 M0 or T3 N1 M0 or any stage III (T4 or N3) p16+ squamous cell carcinoma&#xD;
                  of the oropharynx (AJCC 8th edition staging system)&#xD;
&#xD;
               -  T1-2 N1-3 M0 or T3-4 N0-3 M0 (stage III-IVB) p16+ squamous cell carcinoma of the&#xD;
                  hypopharynx or larynx&#xD;
&#xD;
               -  T1-2 N2-3 M0 or T3-4 N0-3 M0 (stage III-IVB) p16+ squamous cell carcinoma of the&#xD;
                  nasopharynx&#xD;
&#xD;
               -  Inoperable T4 N0-3 M0 (stage IVA-IVB) p16+ squamous cell carcinoma of the oral&#xD;
                  cavity&#xD;
&#xD;
          -  Measurable disease based on RECIST 1.1&#xD;
&#xD;
          -  Adequate hematologic function within 28 days prior to registration&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
          -  Female subject of childbearing potential should have a negative pregnancy test&#xD;
&#xD;
          -  Female subjects of childbearing potential must agree to use an adequate method of&#xD;
             contraception for the course of the study&#xD;
&#xD;
          -  Male subjects must agree to use an adequate method of contraception for the course of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior malignancy within the past 3 years (except non-melanomatous skin cancer and&#xD;
             early stage treated prostate cancer);&#xD;
&#xD;
          -  Prior head and neck radiation, chemotherapy, or immunotherapy;&#xD;
&#xD;
          -  Prior oncologic (radical) surgery to the primary site;&#xD;
&#xD;
          -  Documented evidence of distant metastases;&#xD;
&#xD;
          -  Severe, active co-morbidity defined as follows:&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the last 6 months;&#xD;
&#xD;
               -  Transmural myocardial infarction within the last 6 months;&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration;&#xD;
&#xD;
               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy within 30 days of&#xD;
                  registration;&#xD;
&#xD;
               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects&#xD;
&#xD;
               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition;&#xD;
                  note, however, that HIV testing is not required for entry into this protocol.&#xD;
&#xD;
          -  Any medical or psychiatric illness, which, in the opinion of the principal&#xD;
             investigator, would compromise the patient's ability to tolerate this treatment;&#xD;
&#xD;
          -  Psychiatric/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
          -  Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
          -  Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loren Mell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loren Mell, MD</last_name>
    <phone>(858) 246-0471</phone>
    <email>lmell@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerald Henderson</last_name>
    <email>gehenderson@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alysha Zeoli</last_name>
    </contact>
    <contact_backup>
      <phone>520-694-9056</phone>
    </contact_backup>
    <investigator>
      <last_name>Ricklie Julian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khushbu Singh, MBBS, CCRP</last_name>
      <phone>858-246-2604</phone>
    </contact>
    <investigator>
      <last_name>Loren Mell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pope, CCRP</last_name>
      <phone>203-737-5801</phone>
    </contact>
    <investigator>
      <last_name>Melissa Young, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Facility</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Lemerond</last_name>
      <phone>819-745-2800</phone>
    </contact>
    <investigator>
      <last_name>Jimmy Caudell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Butler</last_name>
      <phone>314-747-8706</phone>
    </contact>
    <investigator>
      <last_name>Douglas Adkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aubrey Hamilton</last_name>
      <phone>513-584-1492</phone>
    </contact>
    <contact_backup>
      <last_name>Sarah Wilson</last_name>
      <phone>513-584-8216</phone>
    </contact_backup>
    <investigator>
      <last_name>Trisha Wise-Draper, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Taylor</last_name>
      <phone>615-875-0060</phone>
    </contact>
    <investigator>
      <last_name>Mike Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Loren Mell, MD</investigator_full_name>
    <investigator_title>Director, Division of Clinical and Translational Research/ Department of Radiation Medicine</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>p16+</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>pd-1</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>T1</keyword>
  <keyword>T2</keyword>
  <keyword>T3</keyword>
  <keyword>N2</keyword>
  <keyword>M0</keyword>
  <keyword>T4</keyword>
  <keyword>N3</keyword>
  <keyword>N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

